Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Enterprise Value (2018 - 2025)

BioNexus Gene Lab's Enterprise Value history spans 8 years, with the latest figure at -$2.9 million for Q3 2025.

  • For Q3 2025, Enterprise Value fell 8.6% year-over-year to -$2.9 million; the TTM value through Sep 2025 reached -$2.9 million, down 8.6%, while the annual FY2024 figure was -$4.4 million, 3.11% up from the prior year.
  • Enterprise Value for Q3 2025 was -$2.9 million at BioNexus Gene Lab, up from -$3.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$1.1 million in Q1 2025 and bottomed at -$5.8 million in Q1 2024.
  • The 5-year median for Enterprise Value is -$2.1 million (2021), against an average of -$2.7 million.
  • The largest annual shift saw Enterprise Value plummeted 221.75% in 2023 before it soared 81.29% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$2.1 million in 2021, then increased by 0.24% to -$2.1 million in 2022, then crashed by 113.21% to -$4.5 million in 2023, then grew by 3.11% to -$4.4 million in 2024, then soared by 33.87% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Enterprise Value are -$2.9 million (Q3 2025), -$3.1 million (Q2 2025), and -$1.1 million (Q1 2025).